@facelabaesthetic's semaglutide BMI claims, fact-checked

What does this video actually claim?

Face Lab Aesthetics, a Bay Area clinic, posted that they won't prescribe semaglutide to patients with BMI below 27, citing "unnecessary risks" and medical guidelines. They position this as prioritizing safety.

The video frames this as responsible medicine. But let's examine whether their BMI cutoff actually matches FDA guidance and clinical evidence.

Do FDA guidelines support a BMI 27 cutoff?

No, the FDA-approved threshold is actually lower. Wegovy (semaglutide 2.4mg) is approved for adults with BMI ≥30, or BMI ≥27 with at least one weight-related condition like hypertension or type 2 diabetes.

The STEP clinical trials that led to approval included patients with BMI ≥27. In STEP 1 (Wilding et al., NEJM, 2021), participants without diabetes had mean BMI of 37.9kg/m² and achieved 14.9% weight loss at 68 weeks with 2.4mg semaglutide.

Face Lab's BMI 27 cutoff is actually more restrictive than FDA guidance, not more permissive.

What about the safety claims?

The "unnecessary risks" framing needs context. Semaglutide's most common side effects are gastrointestinal: nausea (44% vs 9% placebo), diarrhea (30% vs 16%), and vomiting (24% vs 6%) in STEP 1.

These rates weren't dramatically different based on starting BMI within the studied range. The STEP 8 trial (Rubino et al., Lancet, 2022) compared semaglutide 2.4mg to liraglutide 3mg in patients with BMI ≥27 and found similar safety profiles.

Serious adverse events occurred in 9.8% of semaglutide patients versus 6.2% on placebo in STEP 1, but most weren't drug-related.

Is this actually about medical guidelines?

Face Lab frames their policy as following "medical guidelines," but this appears to be their own clinical decision rather than regulatory requirement. Many telehealth platforms prescribe semaglutide to patients meeting FDA criteria.

Their approach might reflect conservative prescribing or business considerations. Some providers set higher BMI thresholds to focus on patients with more severe obesity.

The "alternative treatments" they mention aren't specified, but for patients with BMI 27-30, lifestyle interventions remain first-line according to obesity treatment guidelines.

What should you actually know?

Face Lab got the basic safety profile right but misrepresented FDA guidance. Their BMI 27 floor is stricter than required, not a regulatory mandate.

If you have BMI 27-30 with weight-related health conditions, you do qualify for semaglutide under FDA approval. Different providers have different prescribing practices.

The real safety consideration isn't BMI cutoffs but proper screening, gradual dose escalation (starting at 0.25mg), and monitoring for side effects. At FormBlends, we follow FDA-approved prescribing guidelines while ensuring comprehensive patient evaluation.